Trial Profile

An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 14 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eslicarbazepine acetate (Primary)
Indications Partial epilepsies
Focus Adverse reactions
Sponsors Sunovion Pharmaceuticals

Most Recent Events

11 Jan 2018 Status changed to withdrawn prior to enrolment not due to safety reasons The sponsor received approval for the treatment of partial-onset seizures in patients 4 years of age and older
16 Nov 2017 Status changed from active, no longer recruiting to discontinued.
21 Sep 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com